Oculis Phase 3 DIAMOND Trials Fail Both Endpoints in Diabetic Macular Edema; OCS Stock Plunges

The Quick Take

• Oculis' Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in diabetic macular edema failed to meet both primary and secondary endpoints, sending the stock sharply lower.
• The primary endpoint was mean change in best-corrected visual acuity (BCVA) measured by ETDRS letter score — both studies missed the threshold required for regulatory approval.
• The clinical failure eliminates OCS-01 as a near-term catalyst for Oculis, forcing the company to reassess its pipeline prioritisation and cash runway planning.

Oculis Holding AG reported a dual Phase 3 clinical failure for OCS-01, its lead ophthalmic drug candidate targeting diabetic macular edema (DME), one of the leading causes of vision loss in adults with diabetes globally. Both the DIAMOND-1 and DIAMOND-2 trials missed the primary endpoint — mean improvement in best-corrected visual acuity as measured by ETDRS letter score — along with all secondary endpoints, representing a comprehensive clinical setback. The stock plunged sharply on the announcement, reflecting investor reassessment of the company's near-term commercial prospects.

Phase 3 trial failures in ophthalmology carry outsized market consequences because ophthalmic drug development requires prolonged trial durations and substantial capital expenditure with limited diversification across indication types. For Oculis, this dual-study miss eliminates OCS-01 from the value equation entirely, shifting investor focus to the company's remaining pipeline and whether it has sufficient cash to advance earlier-stage programmes without needing to raise equity at distressed levels. Peer ophthalmic biotech names such as Apellis Pharmaceuticals and IVERIC bio have experienced similar derating events following lead-asset failures, setting a cautionary precedent.

Watch Oculis management's post-trial strategic update for any pivot to other indications or pipeline assets, and monitor its cash burn rate and next major clinical readout timeline. The macro variable determining whether the stock can recover is whether management credibly demonstrates an alternative value pathway — a cash-runway extension through partnerships or licensing would materially change the risk profile. Broader biotech sentiment and the FDA's stance on DME drug approval standards after this high-profile failure may also reshape how similar ophthalmic trials are designed and powered going forward.

Synthesized from 1 source.